Research progress of EGFRvIII targeted immunotherapy in the treatment of glioblastoma
10.16438/j.0513-4870.2022-0754
- VernacularTitle:靶向EGFRvIII免疫疗法在胶质母细胞瘤治疗的研究进展
- Author:
Jun LIU
1
,
2
;
Shen-xia XIE
3
,
4
;
Hai-xia LI
3
,
5
;
Wei SHI
3
,
5
;
Xiao-bing JIANG
6
;
Xuan WANG
6
;
Xiao-mei YANG
3
,
5
;
Xiao-ling LU
1
,
2
Author Information
1. College of Stomatology, Guangxi Medical University, Nanning 530021, China
2. Guangxi Key Laboratory of Nanobody Research, Nanning 530021, China
3. Guangxi Key Laboratory of Nanobody Research, Nanning 530021, China
4. Pharmaceutical College, Guangxi Medical University, Nanning 530021, China
5. School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China
6. Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
- Publication Type:Research Article
- Keywords:
epidermal growth factor receptor variant Ⅲ;
glioblastoma;
targeted antitumor;
immunotherapy;
CAR-T cell;
vaccine
- From:
Acta Pharmaceutica Sinica
2022;57(9):2662-2670
- CountryChina
- Language:Chinese
-
Abstract:
Glioblastoma (GBM) is the most common primary brain tumor, which is prone to recurrence and metastasis with poor prognosis. In recent years, immunotherapy has prolonged the survival of patients with GBM, providing a new option for the treatment of GBM. Target selection is very important for immunotherapy. Epidermal growth factor receptor variant III (EGFRvIII) is highly expressed on the surface of GBM cells in some patients, and EGFRvIII was not expressed in normal tissues. EGFRvIII are pivotal for the occurrence and progression of GBM, various targeted therapy including immunotherapy is promising to improve the efficacy of GBM. Currently, there are various approaches to target EGFRvIII, including humanized monoclonal antibodies, adoptive cell therapies and therapeutic vaccines. In this review, we focus on the preclinical and clinical findings of targeting EGFRvIII for GBM.
